Navigation Links
China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Date:8/8/2008

HARBIN, China, Aug. 8 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that it will conduct a conference call at 10:00 a.m. Eastern Time on August 12, 2008 to discuss its second quarter 2008 financial results.

Joining Mr. Yan-qing Liu, Chairman, CEO and Director of China Sky One Medical, Inc., will be Yu-bo Hao, Board Secretary. The Company plans to issue an earnings announcement prior to the call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 866-573-1052. International callers should dial 702-696-4500. The Conference ID for this call is 59672695.

If you are unable to participate in the call at this time, a replay will be available for fourteen days starting on Tuesday, August 12, 2008 at 12 p.m. Eastern Time. To access the replay, dial 800-642-1687, international callers dial 706-645-9291 Conference ID 59672695.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio-Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products as its primary revenue source. For more information, visit

SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Nepstar Chain Drugstore to Announce Second Quarter 2008 Financial Results on August 27
3. China Pharma Holdings, Inc. Announces Second Quarter 2008 Financial Results
4. China Biologic Products Begins Annual Maintenance of its Production Facilities
5. China Pharma Holdings, Inc. to Host Second Quarter 2008 Earnings Conference Call at 10 a.m. EDT Wednesday August 6, 2008
6. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
7. Global Stem Cell Forum in China Showcases Cutting Edge Research, Focuses on New Findings for iPS Cells
8. China Medical Technologies Adjusts Conversion Rate of Convertible Notes
9. China-Biotics, Inc. Files Application for Nasdaq Listing
10. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
11. China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... 6, 2011 Biodel Inc. (Nasdaq: BIOD ... and CEO of Biodel, will present a corporate update ... January 13, 2011 at 9:30 a.m. Pacific Time (12:30 ... the development of new follow-on formulations of its lead ...
... OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 ... announced today that they will collaborate to develop XmAb ... CD19 and CD32b.  XmAb5871 is currently in late-stage preclinical ... Under the terms of the agreement, Amgen has ...
... DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. (Nasdaq: ... results from its Phase 2b study of RDEA594 in ... treatment of gout, allopurinol.  Allopurinol currently accounts for greater ... prescription medications; however, in controlled trials, only 30-40% of ...
Cached Biology Technology:Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 2Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7
(Date:4/23/2014)... The shale gas boom has transformed the energy ... locations, it could cause conflict among the energy ... resources, say researchers. They add that degraded water ... adequate safeguards. The feature article appears in the ... , Meagan S. Mauter and colleagues point out ...
(Date:4/23/2014)... fiction, or simply cli-fi, is a newly coined term for ... warming. New research from University of Copenhagen shows how these ... simulate the potential consequences of climate change and imagine other ... scientific data on changes in the atmosphere; it is also ... the books we read and the films we see. And ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... conducted at Western University (London, Canada) points to a ... (PTSD): utilising neurofeedback training to alter the plasticity of ... During neurofeedback, intentional control of one,s own ... brain-computer interface, which is able to represent graphically a ...
... those living with gastrointestinal disorders, such as ulcers or Crohn,s ... dietary changes. But what if one day treatment meant doing ... of inflamed or diseased tissues? That is where ... of Technology (MIT) are hoping their new study findings will ...
... Current pledges for greenhouse gas emission reductions are ... reach internationally agreed climate targets, according to new ... research teams coordinated by the International Institute for ... for Climate Impacts Research (PIK)., In the absence ...
Cached Biology News:Neurofeedback tunes key brain networks, improving subjective well-being in PTSD 2Manufacturing a new gut to treat GI diseases 2Continuing with pledge pathways to 2030 could push climate goals out of reach 2
... Synthesis Service provides you with ... knockdown any gene. We offer ... pairs with terminal dT nucleotides), ... lengths of your choice. Each ...
...
...
... Luminex 100 IS System is ideal for ... Beadlyte reagents. This system contains the new, ... by Luminex. The user can design specific ... The system has fully integrated graphing and ...
Biology Products: